|
Jun 2
|
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
|
|
Jun 2
|
ASCO 2025: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
|
|
Jun 2
|
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
|
|
Jun 2
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
|
|
Jun 2
|
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer
|
|
Jun 1
|
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
|
|
Jun 1
|
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk
|
|
Jun 1
|
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
|
|
May 30
|
Danaher Partners With AstraZeneca to Support Precision Medicine
|
|
May 30
|
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
|
|
May 30
|
Danaher and AstraZeneca to develop diagnostic tools and tests
|
|
May 30
|
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
|
|
May 29
|
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
|
|
May 28
|
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
|
|
May 27
|
AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment
|
|
May 27
|
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 23
|
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially
|
|
May 23
|
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
|